Methylphenidat Zentiva

Methylphenidate Hydrochloride, the active ingredient in Methylphenidat Zentiva, is a central nervous system stimulant presented as an oral dosage form for oral use. It is prescribed for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylphenidat Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across all markets.

Methylphenidate Hydrochloride is used in central nervous system stimulant therapy for neurobehavioral disorders.

- Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity in patients. - Narcolepsy: decreases excessive daytime sleepiness and reduces the frequency of sudden sleep attacks.

Methylphenidate Hydrochloride may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake and weight loss. - Headache: mild to moderate cranial pain. - Nervousness: feelings of anxiety or restlessness.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmia. - Psychiatric symptoms: emergence of psychosis, mania, or severe mood changes. - Allergic reactions: rash, pruritus, or anaphylaxis.

When prescribing Methylphenidat Zentiva, clinicians should consider several safety measures.

- Cardiovascular assessment: evaluate blood pressure and heart rate before initiating therapy. - Psychiatric history: monitor for worsening anxiety, aggression, or new psychotic symptoms. - Substance abuse risk: avoid use in individuals with a history of drug dependence. - Growth monitoring: track height and weight in pediatric patients during prolonged treatment. - Drug dependence potential: use only as prescribed and discontinue if misuse is suspected. - Store at below 25°C: keep in the original container, protect from moisture and light.

Methylphenidate can interact with various medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use can cause hypertensive crisis. - Sympathomimetic agents: may amplify cardiovascular side effects such as tachycardia. - Antidepressants that increase serotonin (e.g., SSRIs, SNRIs): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive medications: methylphenidate may reduce their efficacy, requiring dose adjustment. - Anticonvulsants (e.g., carbamazepine): may decrease methylphenidate plasma levels, affecting therapeutic response.